Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Qwerty54321on May 03, 2024 1:57am
128 Views
Post# 36021035

RE:RE:RE:RE:RE:POC in humans has been acheived is that it

RE:RE:RE:RE:RE:POC in humans has been acheived is that it

I do think SPCEO is right. I can't see any significant efficacy update, I can't actually see how any dial moving new data could have arisen. In fact I'd just put these posters into the box-ticking category. They are just doing what any responsible clinical program would/should do in making their long term data publically available.

The only real hope for the cancer program seems to lie with the last 6 part 3 patients, I could easily be wrong.


Saurus100 wrote: Rusty, With all due respect, the press release's title and content say, "It will present long-term efficacy, safety, and pharmacokinetic (PK) data." Therefore, I expect new information regarding long-term efficacy, aren't you? I agree with all of you; we have been disappointed many times... But when you say the data they will present is not focused on efficacy, is that a feeling you have, or is it based on a conversation you had with management?

 

<< Previous
Bullboard Posts
Next >>